abrdn Life Sciences Investors 

$14.97
56
+$0.17+1.15%Minggu Lepas

Statistik

Harga Tertinggi Hari
15.08
Harga Terendah Hari
14.95
52M Tertinggi
15.9
52M Terendah
11.34
Volum
66,744
Volum Purata
94,462
Kapasiti Pasaran
408.89M
Nisbah P/E
11.16
Pendapatan Dividen
13.09%
Dividen
1.96

Akan Datang

Dividen

13.09%Pendapatan Dividen
Pertumbuhan 10T
0.44%
Pertumbuhan 5T
5.73%
Pertumbuhan 3T
3.06%
Pertumbuhan 1T
45.67%

Pendapatan

3JunDijangka
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q1 2022
Q3 2022
Q1 2024
-3.03
-1.58
-0.13
1.32
EPS yang dijangka
N/A
EPS sebenar
N/A

Orang Lain Juga Mengikuti

Senarai ini berdasarkan senarai pantau orang di Stock Events yang mengikuti HQL. Ini bukan cadangan pelaburan.

Peserta

Senarai ini adalah analisis berdasarkan peristiwa pasaran terkini. Ini bukan cadangan pelaburan.
VanEck Biotech
BBH
Kapasiti Pasaran0
VanEck Biotech ETF memberi tumpuan kepada bioteknologi, kawasan utama bagi HQL, menjadikannya pesaing langsung dalam ruang pelaburan sains hayat.
iShares Biotechnology
IBB
Kapasiti Pasaran0
iShares Biotechnology ETF melabur dalam bidang bioteknologi dan farmaseutikal, bersaing secara langsung dengan fokus pelaburan sains hayat dan bioteknologi HQL.
SPDR Biotech
XBI
Kapasiti Pasaran0
SPDR S&P Biotech ETF mempunyai fokus bioteknologi yang luas, bersaing secara langsung dengan strategi pelaburan HQL dalam sektor sains hayat.
First Trust NYSE Arca Biotechnology Index Fund
FBT
Kapasiti Pasaran0
First Trust NYSE Arca Biotechnology Index Fund memberi tumpuan kepada bidang bioteknologi, bersaing dengan pelaburan sains hayat dan bioteknologi HQL.
Invesco Biotechnology & Genome
PBE
Kapasiti Pasaran0
Invesco Dynamic Biotechnology & Genome ETF bersaing dengan melabur dalam bidang bioteknologi, satu bidang tumpuan utama bagi HQL.
Virtus LifeSci Biotech Products
BBP
Kapasiti Pasaran0
Virtus LifeSci Biotech Products ETF memberi tumpuan kepada syarikat-syarikat produk bioteknologi, bersaing dengan strategi pelaburan sains hayat HQL.
ARK Genomic Revolution
ARKG
Kapasiti Pasaran0
ARK Genomic Revolution ETF memberi tumpuan kepada genomik, satu bidang dalam skop pelaburan sains hayat yang lebih luas oleh HQL, menjadikannya pesaing.
ALPS Medical Breakthroughs
SBIO
Kapasiti Pasaran0
ALPS Medical Breakthroughs ETF melabur dalam terobosan perubatan, seringkali dalam bidang bioteknologi, bersaing dengan fokus pelaburan HQL.

Mengenai

Miscellaneous
Investment Trusts/Mutual Funds
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Show more...
CEO
Negara
US

Penyenaraian